iCAD Technology Innovation Day – Expanded ProFound AI Portfolio

Featuring presentations by Key Opinion Leaders Per Hall, MD, PhD (Karolinska Institutet), Axel Gräwingholt, MD (Radiologie am Theater), Joshua A. Nepute, MD (Indiana University Health-Arnett), and Emily F. Conant, MD (University of Pennsylvania Perelman School of Medicine) who will discuss the current landscape for digital breast tomosynthesis (DBT) and the potential for iCAD's recently introduced ProFound AI Risk, the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation based solely on a screening mammogram.

​

iCAD Technology Innovation Day – Expanded Therapy Portfolio

Featuring presentations by Key Opinion Leaders (KOLs) Janie Grumley, MD, FACS (John Wayne Cancer Center), Té Vuong, MD, FRCP (McGill University & Jewish General Hospital), and Santosh Kesari, MD, PhD (John Wayne Cancer Center), who discuss the current treatment landscape and unmet medical need in treating patients with cancers such as breast, rectal, and glioblastoma multiforme. Also highlighted will be recently presented positive clinical data for Xoft® Brain IORT as viable treatment option for glioblastoma multiforme.

​